nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR6—Raloxifene—osteoporosis	0.206	0.309	CbGbCtD
Dihydroergotamine—HTR2B—Raloxifene—osteoporosis	0.184	0.276	CbGbCtD
Dihydroergotamine—ABCB1—Ethinyl Estradiol—osteoporosis	0.0368	0.0552	CbGbCtD
Dihydroergotamine—CYP3A4—Estropipate—osteoporosis	0.0342	0.0514	CbGbCtD
Dihydroergotamine—CYP3A4—Calcitriol—osteoporosis	0.0342	0.0514	CbGbCtD
Dihydroergotamine—CYP3A4—Ergocalciferol—osteoporosis	0.0274	0.0411	CbGbCtD
Dihydroergotamine—ABCB1—Conjugated Estrogens—osteoporosis	0.027	0.0405	CbGbCtD
Dihydroergotamine—ABCB1—Estradiol—osteoporosis	0.0237	0.0356	CbGbCtD
Dihydroergotamine—CYP3A4—Raloxifene—osteoporosis	0.0228	0.0343	CbGbCtD
Dihydroergotamine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0221	0.0331	CbGbCtD
Dihydroergotamine—CYP3A4—Cholecalciferol—osteoporosis	0.0176	0.0265	CbGbCtD
Dihydroergotamine—CYP3A4—Conjugated Estrogens—osteoporosis	0.0162	0.0243	CbGbCtD
Dihydroergotamine—CYP3A4—Estradiol—osteoporosis	0.0142	0.0213	CbGbCtD
Dihydroergotamine—Body temperature increased—Raloxifene—osteoporosis	0.000323	0.0011	CcSEcCtD
Dihydroergotamine—Urticaria—Ibandronate—osteoporosis	0.000321	0.0011	CcSEcCtD
Dihydroergotamine—Malaise—Zoledronate—osteoporosis	0.00032	0.00109	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ibandronate—osteoporosis	0.00032	0.00109	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ibandronate—osteoporosis	0.00032	0.00109	CcSEcCtD
Dihydroergotamine—Confusional state—Pamidronate—osteoporosis	0.000319	0.00109	CcSEcCtD
Dihydroergotamine—Vertigo—Zoledronate—osteoporosis	0.000319	0.00109	CcSEcCtD
Dihydroergotamine—Oedema—Pamidronate—osteoporosis	0.000317	0.00108	CcSEcCtD
Dihydroergotamine—Rhinitis—Estradiol—osteoporosis	0.000315	0.00108	CcSEcCtD
Dihydroergotamine—Urticaria—Calcitriol—osteoporosis	0.000314	0.00108	CcSEcCtD
Dihydroergotamine—Palpitations—Zoledronate—osteoporosis	0.000313	0.00107	CcSEcCtD
Dihydroergotamine—Abdominal pain—Calcitriol—osteoporosis	0.000313	0.00107	CcSEcCtD
Dihydroergotamine—Body temperature increased—Calcitriol—osteoporosis	0.000313	0.00107	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Estradiol—osteoporosis	0.000312	0.00107	CcSEcCtD
Dihydroergotamine—Shock—Pamidronate—osteoporosis	0.000312	0.00107	CcSEcCtD
Dihydroergotamine—Pharyngitis—Estradiol—osteoporosis	0.000311	0.00107	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Estropipate—osteoporosis	0.000311	0.00106	CcSEcCtD
Dihydroergotamine—Vomiting—Etidronic acid—osteoporosis	0.00031	0.00106	CcSEcCtD
Dihydroergotamine—Tachycardia—Pamidronate—osteoporosis	0.000309	0.00106	CcSEcCtD
Dihydroergotamine—Rash—Etidronic acid—osteoporosis	0.000307	0.00105	CcSEcCtD
Dihydroergotamine—Dermatitis—Etidronic acid—osteoporosis	0.000307	0.00105	CcSEcCtD
Dihydroergotamine—Vertigo—Conjugated Estrogens—osteoporosis	0.000307	0.00105	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Pamidronate—osteoporosis	0.000306	0.00105	CcSEcCtD
Dihydroergotamine—Hypertension—Zoledronate—osteoporosis	0.000306	0.00105	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Alendronate—osteoporosis	0.000306	0.00105	CcSEcCtD
Dihydroergotamine—Headache—Etidronic acid—osteoporosis	0.000305	0.00104	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000304	0.00104	CcSEcCtD
Dihydroergotamine—Asthenia—Estropipate—osteoporosis	0.000303	0.00103	CcSEcCtD
Dihydroergotamine—Visual impairment—Estradiol—osteoporosis	0.000302	0.00103	CcSEcCtD
Dihydroergotamine—Anorexia—Pamidronate—osteoporosis	0.000302	0.00103	CcSEcCtD
Dihydroergotamine—Arthralgia—Zoledronate—osteoporosis	0.000302	0.00103	CcSEcCtD
Dihydroergotamine—Myalgia—Zoledronate—osteoporosis	0.000302	0.00103	CcSEcCtD
Dihydroergotamine—Palpitations—Conjugated Estrogens—osteoporosis	0.000302	0.00103	CcSEcCtD
Dihydroergotamine—Insomnia—Risedronate—osteoporosis	0.000301	0.00103	CcSEcCtD
Dihydroergotamine—Anxiety—Zoledronate—osteoporosis	0.000301	0.00103	CcSEcCtD
Dihydroergotamine—Paraesthesia—Risedronate—osteoporosis	0.000299	0.00102	CcSEcCtD
Dihydroergotamine—Pruritus—Estropipate—osteoporosis	0.000298	0.00102	CcSEcCtD
Dihydroergotamine—Discomfort—Zoledronate—osteoporosis	0.000298	0.00102	CcSEcCtD
Dihydroergotamine—Asthenia—Alendronate—osteoporosis	0.000298	0.00102	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ibandronate—osteoporosis	0.000298	0.00102	CcSEcCtD
Dihydroergotamine—Dyspnoea—Risedronate—osteoporosis	0.000297	0.00102	CcSEcCtD
Dihydroergotamine—Hypotension—Pamidronate—osteoporosis	0.000296	0.00101	CcSEcCtD
Dihydroergotamine—Dry mouth—Zoledronate—osteoporosis	0.000295	0.00101	CcSEcCtD
Dihydroergotamine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000295	0.00101	CcSEcCtD
Dihydroergotamine—Pruritus—Alendronate—osteoporosis	0.000294	0.00101	CcSEcCtD
Dihydroergotamine—Dyspepsia—Risedronate—osteoporosis	0.000293	0.001	CcSEcCtD
Dihydroergotamine—Tinnitus—Estradiol—osteoporosis	0.000293	0.001	CcSEcCtD
Dihydroergotamine—Confusional state—Zoledronate—osteoporosis	0.000292	0.000998	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Calcitriol—osteoporosis	0.000292	0.000997	CcSEcCtD
Dihydroergotamine—Flushing—Estradiol—osteoporosis	0.000291	0.000996	CcSEcCtD
Dihydroergotamine—Myalgia—Conjugated Estrogens—osteoporosis	0.000291	0.000994	CcSEcCtD
Dihydroergotamine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000291	0.000994	CcSEcCtD
Dihydroergotamine—Asthenia—Ibandronate—osteoporosis	0.00029	0.000992	CcSEcCtD
Dihydroergotamine—Anxiety—Conjugated Estrogens—osteoporosis	0.00029	0.000991	CcSEcCtD
Dihydroergotamine—Nausea—Etidronic acid—osteoporosis	0.000289	0.00099	CcSEcCtD
Dihydroergotamine—Oedema—Zoledronate—osteoporosis	0.000289	0.00099	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000289	0.000987	CcSEcCtD
Dihydroergotamine—Diarrhoea—Estropipate—osteoporosis	0.000288	0.000987	CcSEcCtD
Dihydroergotamine—Fatigue—Risedronate—osteoporosis	0.000287	0.000983	CcSEcCtD
Dihydroergotamine—Insomnia—Pamidronate—osteoporosis	0.000286	0.00098	CcSEcCtD
Dihydroergotamine—Pruritus—Ibandronate—osteoporosis	0.000286	0.000979	CcSEcCtD
Dihydroergotamine—Pain—Risedronate—osteoporosis	0.000285	0.000975	CcSEcCtD
Dihydroergotamine—Shock—Zoledronate—osteoporosis	0.000285	0.000974	CcSEcCtD
Dihydroergotamine—Paraesthesia—Pamidronate—osteoporosis	0.000284	0.000973	CcSEcCtD
Dihydroergotamine—Diarrhoea—Alendronate—osteoporosis	0.000284	0.000972	CcSEcCtD
Dihydroergotamine—Asthenia—Calcitriol—osteoporosis	0.000284	0.000971	CcSEcCtD
Dihydroergotamine—Dyspnoea—Pamidronate—osteoporosis	0.000282	0.000966	CcSEcCtD
Dihydroergotamine—Tachycardia—Zoledronate—osteoporosis	0.000282	0.000966	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000282	0.000963	CcSEcCtD
Dihydroergotamine—Chills—Estradiol—osteoporosis	0.000282	0.000963	CcSEcCtD
Dihydroergotamine—Somnolence—Pamidronate—osteoporosis	0.000282	0.000963	CcSEcCtD
Dihydroergotamine—Pruritus—Calcitriol—osteoporosis	0.00028	0.000958	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Zoledronate—osteoporosis	0.00028	0.000957	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000279	0.000956	CcSEcCtD
Dihydroergotamine—Diarrhoea—Raloxifene—osteoporosis	0.000279	0.000956	CcSEcCtD
Dihydroergotamine—Dyspepsia—Pamidronate—osteoporosis	0.000279	0.000954	CcSEcCtD
Dihydroergotamine—Dizziness—Estropipate—osteoporosis	0.000279	0.000954	CcSEcCtD
Dihydroergotamine—Oedema—Conjugated Estrogens—osteoporosis	0.000279	0.000953	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ibandronate—osteoporosis	0.000277	0.000946	CcSEcCtD
Dihydroergotamine—Anorexia—Zoledronate—osteoporosis	0.000276	0.000943	CcSEcCtD
Dihydroergotamine—Decreased appetite—Pamidronate—osteoporosis	0.000275	0.000942	CcSEcCtD
Dihydroergotamine—Dizziness—Alendronate—osteoporosis	0.000275	0.000939	CcSEcCtD
Dihydroergotamine—Shock—Conjugated Estrogens—osteoporosis	0.000274	0.000938	CcSEcCtD
Dihydroergotamine—Fatigue—Pamidronate—osteoporosis	0.000273	0.000934	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Risedronate—osteoporosis	0.000272	0.000932	CcSEcCtD
Dihydroergotamine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000272	0.00093	CcSEcCtD
Dihydroergotamine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000271	0.000929	CcSEcCtD
Dihydroergotamine—Pain—Pamidronate—osteoporosis	0.000271	0.000927	CcSEcCtD
Dihydroergotamine—Diarrhoea—Calcitriol—osteoporosis	0.000271	0.000926	CcSEcCtD
Dihydroergotamine—Hypotension—Zoledronate—osteoporosis	0.00027	0.000925	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00027	0.000924	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00027	0.000924	CcSEcCtD
Dihydroergotamine—Dizziness—Raloxifene—osteoporosis	0.00027	0.000924	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000269	0.000921	CcSEcCtD
Dihydroergotamine—Tension—Estradiol—osteoporosis	0.000268	0.000917	CcSEcCtD
Dihydroergotamine—Vomiting—Estropipate—osteoporosis	0.000268	0.000917	CcSEcCtD
Dihydroergotamine—Dizziness—Ibandronate—osteoporosis	0.000267	0.000915	CcSEcCtD
Dihydroergotamine—Rash—Estropipate—osteoporosis	0.000266	0.000909	CcSEcCtD
Dihydroergotamine—Dermatitis—Estropipate—osteoporosis	0.000266	0.000909	CcSEcCtD
Dihydroergotamine—Anorexia—Conjugated Estrogens—osteoporosis	0.000266	0.000908	CcSEcCtD
Dihydroergotamine—Nervousness—Estradiol—osteoporosis	0.000265	0.000908	CcSEcCtD
Dihydroergotamine—Urticaria—Risedronate—osteoporosis	0.000265	0.000905	CcSEcCtD
Dihydroergotamine—Headache—Estropipate—osteoporosis	0.000264	0.000904	CcSEcCtD
Dihydroergotamine—Vomiting—Alendronate—osteoporosis	0.000264	0.000903	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000264	0.000902	CcSEcCtD
Dihydroergotamine—Body temperature increased—Risedronate—osteoporosis	0.000263	0.000901	CcSEcCtD
Dihydroergotamine—Abdominal pain—Risedronate—osteoporosis	0.000263	0.000901	CcSEcCtD
Dihydroergotamine—Muscle spasms—Estradiol—osteoporosis	0.000263	0.000898	CcSEcCtD
Dihydroergotamine—Rash—Alendronate—osteoporosis	0.000262	0.000896	CcSEcCtD
Dihydroergotamine—Insomnia—Zoledronate—osteoporosis	0.000262	0.000895	CcSEcCtD
Dihydroergotamine—Dermatitis—Alendronate—osteoporosis	0.000262	0.000895	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Pamidronate—osteoporosis	0.000261	0.000893	CcSEcCtD
Dihydroergotamine—Hypotension—Conjugated Estrogens—osteoporosis	0.00026	0.00089	CcSEcCtD
Dihydroergotamine—Headache—Alendronate—osteoporosis	0.00026	0.00089	CcSEcCtD
Dihydroergotamine—Paraesthesia—Zoledronate—osteoporosis	0.00026	0.000889	CcSEcCtD
Dihydroergotamine—Vomiting—Raloxifene—osteoporosis	0.00026	0.000888	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000259	0.000886	CcSEcCtD
Dihydroergotamine—Dyspnoea—Zoledronate—osteoporosis	0.000258	0.000882	CcSEcCtD
Dihydroergotamine—Rash—Raloxifene—osteoporosis	0.000258	0.000881	CcSEcCtD
Dihydroergotamine—Dermatitis—Raloxifene—osteoporosis	0.000257	0.00088	CcSEcCtD
Dihydroergotamine—Somnolence—Zoledronate—osteoporosis	0.000257	0.00088	CcSEcCtD
Dihydroergotamine—Vomiting—Ibandronate—osteoporosis	0.000257	0.000879	CcSEcCtD
Dihydroergotamine—Tremor—Estradiol—osteoporosis	0.000256	0.000876	CcSEcCtD
Dihydroergotamine—Headache—Raloxifene—osteoporosis	0.000256	0.000875	CcSEcCtD
Dihydroergotamine—Rash—Ibandronate—osteoporosis	0.000255	0.000872	CcSEcCtD
Dihydroergotamine—Dermatitis—Ibandronate—osteoporosis	0.000255	0.000871	CcSEcCtD
Dihydroergotamine—Dyspepsia—Zoledronate—osteoporosis	0.000255	0.000871	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000254	0.000868	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Estradiol—osteoporosis	0.000253	0.000867	CcSEcCtD
Dihydroergotamine—Headache—Ibandronate—osteoporosis	0.000253	0.000866	CcSEcCtD
Dihydroergotamine—Insomnia—Conjugated Estrogens—osteoporosis	0.000252	0.000862	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000252	0.000861	CcSEcCtD
Dihydroergotamine—Vomiting—Calcitriol—osteoporosis	0.000252	0.000861	CcSEcCtD
Dihydroergotamine—Decreased appetite—Zoledronate—osteoporosis	0.000252	0.00086	CcSEcCtD
Dihydroergotamine—Agitation—Estradiol—osteoporosis	0.000251	0.000859	CcSEcCtD
Dihydroergotamine—Nausea—Estropipate—osteoporosis	0.00025	0.000857	CcSEcCtD
Dihydroergotamine—Abdominal pain—Pamidronate—osteoporosis	0.00025	0.000857	CcSEcCtD
Dihydroergotamine—Body temperature increased—Pamidronate—osteoporosis	0.00025	0.000857	CcSEcCtD
Dihydroergotamine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00025	0.000856	CcSEcCtD
Dihydroergotamine—Rash—Calcitriol—osteoporosis	0.00025	0.000854	CcSEcCtD
Dihydroergotamine—Fatigue—Zoledronate—osteoporosis	0.000249	0.000853	CcSEcCtD
Dihydroergotamine—Dermatitis—Calcitriol—osteoporosis	0.000249	0.000853	CcSEcCtD
Dihydroergotamine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000248	0.00085	CcSEcCtD
Dihydroergotamine—Headache—Calcitriol—osteoporosis	0.000248	0.000848	CcSEcCtD
Dihydroergotamine—Somnolence—Conjugated Estrogens—osteoporosis	0.000248	0.000847	CcSEcCtD
Dihydroergotamine—Pain—Zoledronate—osteoporosis	0.000247	0.000846	CcSEcCtD
Dihydroergotamine—Nausea—Alendronate—osteoporosis	0.000247	0.000844	CcSEcCtD
Dihydroergotamine—Malaise—Estradiol—osteoporosis	0.000246	0.000843	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Risedronate—osteoporosis	0.000245	0.00084	CcSEcCtD
Dihydroergotamine—Vertigo—Estradiol—osteoporosis	0.000245	0.00084	CcSEcCtD
Dihydroergotamine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000245	0.000839	CcSEcCtD
Dihydroergotamine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000245	0.000839	CcSEcCtD
Dihydroergotamine—Nausea—Raloxifene—osteoporosis	0.000243	0.00083	CcSEcCtD
Dihydroergotamine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000242	0.000828	CcSEcCtD
Dihydroergotamine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000242	0.000827	CcSEcCtD
Dihydroergotamine—Palpitations—Estradiol—osteoporosis	0.000241	0.000826	CcSEcCtD
Dihydroergotamine—Fatigue—Conjugated Estrogens—osteoporosis	0.00024	0.000822	CcSEcCtD
Dihydroergotamine—Nausea—Ibandronate—osteoporosis	0.00024	0.000822	CcSEcCtD
Dihydroergotamine—Asthenia—Risedronate—osteoporosis	0.000239	0.000818	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Zoledronate—osteoporosis	0.000238	0.000816	CcSEcCtD
Dihydroergotamine—Pain—Conjugated Estrogens—osteoporosis	0.000238	0.000815	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000237	0.000809	CcSEcCtD
Dihydroergotamine—Hypertension—Estradiol—osteoporosis	0.000236	0.000807	CcSEcCtD
Dihydroergotamine—Pruritus—Risedronate—osteoporosis	0.000236	0.000806	CcSEcCtD
Dihydroergotamine—Nausea—Calcitriol—osteoporosis	0.000235	0.000804	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000234	0.0008	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Pamidronate—osteoporosis	0.000233	0.000798	CcSEcCtD
Dihydroergotamine—Myalgia—Estradiol—osteoporosis	0.000233	0.000796	CcSEcCtD
Dihydroergotamine—Arthralgia—Estradiol—osteoporosis	0.000233	0.000796	CcSEcCtD
Dihydroergotamine—Anxiety—Estradiol—osteoporosis	0.000232	0.000793	CcSEcCtD
Dihydroergotamine—Urticaria—Zoledronate—osteoporosis	0.00023	0.000786	CcSEcCtD
Dihydroergotamine—Discomfort—Estradiol—osteoporosis	0.00023	0.000786	CcSEcCtD
Dihydroergotamine—Body temperature increased—Zoledronate—osteoporosis	0.000229	0.000782	CcSEcCtD
Dihydroergotamine—Abdominal pain—Zoledronate—osteoporosis	0.000229	0.000782	CcSEcCtD
Dihydroergotamine—Diarrhoea—Risedronate—osteoporosis	0.000228	0.00078	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000228	0.000779	CcSEcCtD
Dihydroergotamine—Dry mouth—Estradiol—osteoporosis	0.000227	0.000778	CcSEcCtD
Dihydroergotamine—Asthenia—Pamidronate—osteoporosis	0.000227	0.000777	CcSEcCtD
Dihydroergotamine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000226	0.000773	CcSEcCtD
Dihydroergotamine—Confusional state—Estradiol—osteoporosis	0.000225	0.000769	CcSEcCtD
Dihydroergotamine—Pruritus—Pamidronate—osteoporosis	0.000224	0.000767	CcSEcCtD
Dihydroergotamine—Oedema—Estradiol—osteoporosis	0.000223	0.000763	CcSEcCtD
Dihydroergotamine—Urticaria—Conjugated Estrogens—osteoporosis	0.000221	0.000757	CcSEcCtD
Dihydroergotamine—Dizziness—Risedronate—osteoporosis	0.00022	0.000754	CcSEcCtD
Dihydroergotamine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00022	0.000753	CcSEcCtD
Dihydroergotamine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00022	0.000753	CcSEcCtD
Dihydroergotamine—Shock—Estradiol—osteoporosis	0.000219	0.00075	CcSEcCtD
Dihydroergotamine—Tachycardia—Estradiol—osteoporosis	0.000218	0.000744	CcSEcCtD
Dihydroergotamine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000217	0.000743	CcSEcCtD
Dihydroergotamine—Diarrhoea—Pamidronate—osteoporosis	0.000217	0.000741	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Estradiol—osteoporosis	0.000216	0.000737	CcSEcCtD
Dihydroergotamine—Rash—Ethinyl Estradiol—osteoporosis	0.000215	0.000737	CcSEcCtD
Dihydroergotamine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000215	0.000736	CcSEcCtD
Dihydroergotamine—Headache—Ethinyl Estradiol—osteoporosis	0.000214	0.000732	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Zoledronate—osteoporosis	0.000213	0.000729	CcSEcCtD
Dihydroergotamine—Vomiting—Risedronate—osteoporosis	0.000212	0.000725	CcSEcCtD
Dihydroergotamine—Rash—Risedronate—osteoporosis	0.00021	0.000719	CcSEcCtD
Dihydroergotamine—Dermatitis—Risedronate—osteoporosis	0.00021	0.000718	CcSEcCtD
Dihydroergotamine—Dizziness—Pamidronate—osteoporosis	0.000209	0.000717	CcSEcCtD
Dihydroergotamine—Headache—Risedronate—osteoporosis	0.000209	0.000714	CcSEcCtD
Dihydroergotamine—Asthenia—Zoledronate—osteoporosis	0.000208	0.00071	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000205	0.000702	CcSEcCtD
Dihydroergotamine—Pruritus—Zoledronate—osteoporosis	0.000205	0.0007	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000203	0.000695	CcSEcCtD
Dihydroergotamine—Nausea—Ethinyl Estradiol—osteoporosis	0.000203	0.000694	CcSEcCtD
Dihydroergotamine—Insomnia—Estradiol—osteoporosis	0.000202	0.00069	CcSEcCtD
Dihydroergotamine—Vomiting—Pamidronate—osteoporosis	0.000201	0.000689	CcSEcCtD
Dihydroergotamine—Paraesthesia—Estradiol—osteoporosis	0.0002	0.000685	CcSEcCtD
Dihydroergotamine—Asthenia—Conjugated Estrogens—osteoporosis	0.0002	0.000684	CcSEcCtD
Dihydroergotamine—Rash—Pamidronate—osteoporosis	0.0002	0.000683	CcSEcCtD
Dihydroergotamine—Dermatitis—Pamidronate—osteoporosis	0.0002	0.000683	CcSEcCtD
Dihydroergotamine—Dyspnoea—Estradiol—osteoporosis	0.000199	0.00068	CcSEcCtD
Dihydroergotamine—Headache—Pamidronate—osteoporosis	0.000198	0.000679	CcSEcCtD
Dihydroergotamine—Somnolence—Estradiol—osteoporosis	0.000198	0.000678	CcSEcCtD
Dihydroergotamine—Diarrhoea—Zoledronate—osteoporosis	0.000198	0.000677	CcSEcCtD
Dihydroergotamine—Nausea—Risedronate—osteoporosis	0.000198	0.000677	CcSEcCtD
Dihydroergotamine—Pruritus—Conjugated Estrogens—osteoporosis	0.000197	0.000674	CcSEcCtD
Dihydroergotamine—Dyspepsia—Estradiol—osteoporosis	0.000196	0.000671	CcSEcCtD
Dihydroergotamine—Decreased appetite—Estradiol—osteoporosis	0.000194	0.000663	CcSEcCtD
Dihydroergotamine—Fatigue—Estradiol—osteoporosis	0.000192	0.000658	CcSEcCtD
Dihydroergotamine—Dizziness—Zoledronate—osteoporosis	0.000191	0.000654	CcSEcCtD
Dihydroergotamine—Pain—Estradiol—osteoporosis	0.000191	0.000652	CcSEcCtD
Dihydroergotamine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000191	0.000652	CcSEcCtD
Dihydroergotamine—Nausea—Pamidronate—osteoporosis	0.000188	0.000644	CcSEcCtD
Dihydroergotamine—Dizziness—Conjugated Estrogens—osteoporosis	0.000184	0.00063	CcSEcCtD
Dihydroergotamine—Vomiting—Zoledronate—osteoporosis	0.000184	0.000629	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Estradiol—osteoporosis	0.000184	0.000629	CcSEcCtD
Dihydroergotamine—Rash—Zoledronate—osteoporosis	0.000182	0.000624	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Estradiol—osteoporosis	0.000182	0.000624	CcSEcCtD
Dihydroergotamine—Dermatitis—Zoledronate—osteoporosis	0.000182	0.000623	CcSEcCtD
Dihydroergotamine—Headache—Zoledronate—osteoporosis	0.000181	0.00062	CcSEcCtD
Dihydroergotamine—Vomiting—Conjugated Estrogens—osteoporosis	0.000177	0.000606	CcSEcCtD
Dihydroergotamine—Urticaria—Estradiol—osteoporosis	0.000177	0.000606	CcSEcCtD
Dihydroergotamine—Abdominal pain—Estradiol—osteoporosis	0.000176	0.000603	CcSEcCtD
Dihydroergotamine—Body temperature increased—Estradiol—osteoporosis	0.000176	0.000603	CcSEcCtD
Dihydroergotamine—Rash—Conjugated Estrogens—osteoporosis	0.000176	0.000601	CcSEcCtD
Dihydroergotamine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000175	0.0006	CcSEcCtD
Dihydroergotamine—Headache—Conjugated Estrogens—osteoporosis	0.000175	0.000597	CcSEcCtD
Dihydroergotamine—Nausea—Zoledronate—osteoporosis	0.000172	0.000588	CcSEcCtD
Dihydroergotamine—Nausea—Conjugated Estrogens—osteoporosis	0.000165	0.000566	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Estradiol—osteoporosis	0.000164	0.000562	CcSEcCtD
Dihydroergotamine—Asthenia—Estradiol—osteoporosis	0.00016	0.000547	CcSEcCtD
Dihydroergotamine—Pruritus—Estradiol—osteoporosis	0.000158	0.00054	CcSEcCtD
Dihydroergotamine—Diarrhoea—Estradiol—osteoporosis	0.000153	0.000522	CcSEcCtD
Dihydroergotamine—Dizziness—Estradiol—osteoporosis	0.000147	0.000504	CcSEcCtD
Dihydroergotamine—Vomiting—Estradiol—osteoporosis	0.000142	0.000485	CcSEcCtD
Dihydroergotamine—Rash—Estradiol—osteoporosis	0.000141	0.000481	CcSEcCtD
Dihydroergotamine—Dermatitis—Estradiol—osteoporosis	0.00014	0.00048	CcSEcCtD
Dihydroergotamine—Headache—Estradiol—osteoporosis	0.00014	0.000478	CcSEcCtD
Dihydroergotamine—Nausea—Estradiol—osteoporosis	0.000132	0.000453	CcSEcCtD
Dihydroergotamine—HTR2B—Signaling Pathways—RAP1A—osteoporosis	3.26e-05	0.000792	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—IDH2—osteoporosis	3.25e-05	0.00079	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGA—osteoporosis	3.24e-05	0.000787	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WNT1—osteoporosis	3.24e-05	0.000786	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CNR2—osteoporosis	3.23e-05	0.000785	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.22e-05	0.000782	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGA—osteoporosis	3.22e-05	0.000781	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—ADCY5—osteoporosis	3.21e-05	0.00078	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TLN1—osteoporosis	3.21e-05	0.000779	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MGLL—osteoporosis	3.2e-05	0.000777	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—ADCY5—osteoporosis	3.19e-05	0.000776	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ATIC—osteoporosis	3.19e-05	0.000775	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PNP—osteoporosis	3.19e-05	0.000775	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NFATC1—osteoporosis	3.18e-05	0.000773	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—ADCY5—osteoporosis	3.17e-05	0.00077	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DKK1—osteoporosis	3.16e-05	0.000767	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGA—osteoporosis	3.15e-05	0.000765	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LRP5—osteoporosis	3.12e-05	0.000758	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—ADCY5—osteoporosis	3.1e-05	0.000754	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP27A1—osteoporosis	3.06e-05	0.000743	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WNT1—osteoporosis	3.04e-05	0.000739	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTHLH—osteoporosis	3.01e-05	0.000732	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—BMP2—osteoporosis	3.01e-05	0.000732	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—BMP2—osteoporosis	2.99e-05	0.000726	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTHLH—osteoporosis	2.99e-05	0.000726	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LRP6—osteoporosis	2.99e-05	0.000725	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ACP5—osteoporosis	2.97e-05	0.000723	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PTHLH—osteoporosis	2.97e-05	0.000721	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGA—osteoporosis	2.96e-05	0.000718	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGB—osteoporosis	2.95e-05	0.000716	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTHLH—osteoporosis	2.93e-05	0.000711	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—BMP2—osteoporosis	2.93e-05	0.000711	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGB—osteoporosis	2.93e-05	0.000711	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—ADCY5—osteoporosis	2.91e-05	0.000708	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CALCA—osteoporosis	2.88e-05	0.000699	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGB—osteoporosis	2.86e-05	0.000696	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PSMA5—osteoporosis	2.85e-05	0.000691	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PSMA2—osteoporosis	2.85e-05	0.000691	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PSMA2—osteoporosis	2.82e-05	0.000686	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PSMA5—osteoporosis	2.82e-05	0.000686	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—P4HB—osteoporosis	2.77e-05	0.000672	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TPI1—osteoporosis	2.77e-05	0.000672	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PSMA5—osteoporosis	2.77e-05	0.000672	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PSMA2—osteoporosis	2.77e-05	0.000672	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTHLH—osteoporosis	2.75e-05	0.000668	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—BMP2—osteoporosis	2.75e-05	0.000668	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—OXCT1—osteoporosis	2.71e-05	0.000659	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CA2—osteoporosis	2.71e-05	0.000659	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTH—osteoporosis	2.69e-05	0.000654	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGB—osteoporosis	2.69e-05	0.000654	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.66e-05	0.000647	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—POMC—osteoporosis	2.66e-05	0.000647	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CALCA—osteoporosis	2.65e-05	0.000644	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MGLL—osteoporosis	2.65e-05	0.000643	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RAP1A—osteoporosis	2.64e-05	0.000642	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CALCA—osteoporosis	2.63e-05	0.000639	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CNR2—osteoporosis	2.62e-05	0.000637	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CALCA—osteoporosis	2.61e-05	0.000634	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—ADCY5—osteoporosis	2.6e-05	0.000632	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—P4HB—osteoporosis	2.6e-05	0.000632	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PSMA2—osteoporosis	2.6e-05	0.000631	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PSMA5—osteoporosis	2.6e-05	0.000631	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—POMC—osteoporosis	2.59e-05	0.000628	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFATC1—osteoporosis	2.58e-05	0.000627	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CALCA—osteoporosis	2.58e-05	0.000626	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—POMC—osteoporosis	2.57e-05	0.000623	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DKK1—osteoporosis	2.56e-05	0.000622	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GAPDH—osteoporosis	2.55e-05	0.00062	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TLN1—osteoporosis	2.52e-05	0.000612	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—POMC—osteoporosis	2.51e-05	0.000611	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—RAP1A—osteoporosis	2.49e-05	0.000604	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WNT1—osteoporosis	2.47e-05	0.000599	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CALCA—osteoporosis	2.42e-05	0.000588	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KL—osteoporosis	2.41e-05	0.000585	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—POMC—osteoporosis	2.41e-05	0.000584	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGA—osteoporosis	2.4e-05	0.000583	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KL—osteoporosis	2.39e-05	0.00058	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ADCY5—osteoporosis	2.36e-05	0.000574	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—POMC—osteoporosis	2.36e-05	0.000573	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—POMC—osteoporosis	2.35e-05	0.000571	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KL—osteoporosis	2.34e-05	0.000568	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—POMC—osteoporosis	2.33e-05	0.000566	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6R—osteoporosis	2.29e-05	0.000557	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IGF1—osteoporosis	2.29e-05	0.000556	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—POMC—osteoporosis	2.28e-05	0.000554	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6R—osteoporosis	2.27e-05	0.000552	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FDPS—osteoporosis	2.27e-05	0.000551	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PKM—osteoporosis	2.27e-05	0.000551	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—IDH2—osteoporosis	2.25e-05	0.000546	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTHLH—osteoporosis	2.23e-05	0.000542	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BMP2—osteoporosis	2.23e-05	0.000542	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6R—osteoporosis	2.23e-05	0.000541	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KL—osteoporosis	2.2e-05	0.000534	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGB—osteoporosis	2.18e-05	0.00053	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—P4HB—osteoporosis	2.17e-05	0.000528	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PGLS—osteoporosis	2.15e-05	0.000522	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPD2—osteoporosis	2.15e-05	0.000522	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—POMC—osteoporosis	2.14e-05	0.000521	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTH—osteoporosis	2.12e-05	0.000514	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP27A1—osteoporosis	2.11e-05	0.000514	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PSMA5—osteoporosis	2.11e-05	0.000512	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PSMA2—osteoporosis	2.11e-05	0.000512	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6R—osteoporosis	2.09e-05	0.000508	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	2.08e-05	0.000505	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.08e-05	0.000504	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.07e-05	0.000503	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CNR2—osteoporosis	2.06e-05	0.000501	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ACP5—osteoporosis	2.06e-05	0.0005	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	2.05e-05	0.000497	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	2.03e-05	0.000493	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DKK1—osteoporosis	2.01e-05	0.000489	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ENO1—osteoporosis	2.01e-05	0.000488	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PSMA2—osteoporosis	1.98e-05	0.000481	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PSMA5—osteoporosis	1.98e-05	0.000481	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ATIC—osteoporosis	1.97e-05	0.000478	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PNP—osteoporosis	1.97e-05	0.000478	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CALCA—osteoporosis	1.96e-05	0.000477	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WNT1—osteoporosis	1.94e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.94e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.93e-05	0.00047	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—POMC—osteoporosis	1.91e-05	0.000465	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPI1—osteoporosis	1.91e-05	0.000465	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADCY5—osteoporosis	1.89e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGA—osteoporosis	1.89e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADCY5—osteoporosis	1.87e-05	0.000455	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	1.86e-05	0.000451	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADCY5—osteoporosis	1.83e-05	0.000445	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SPP1—osteoporosis	1.83e-05	0.000443	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SPP1—osteoporosis	1.81e-05	0.00044	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—P4HB—osteoporosis	1.8e-05	0.000437	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KL—osteoporosis	1.78e-05	0.000433	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SPP1—osteoporosis	1.77e-05	0.000431	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GAPDH—osteoporosis	1.76e-05	0.000429	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	1.75e-05	0.000426	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BMP2—osteoporosis	1.75e-05	0.000426	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—osteoporosis	1.74e-05	0.000422	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADCY5—osteoporosis	1.72e-05	0.000418	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RAP1A—osteoporosis	1.72e-05	0.000418	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGB—osteoporosis	1.72e-05	0.000417	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6R—osteoporosis	1.7e-05	0.000412	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CA2—osteoporosis	1.67e-05	0.000406	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—OXCT1—osteoporosis	1.67e-05	0.000406	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SPP1—osteoporosis	1.67e-05	0.000405	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.66e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.66e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IRS2—osteoporosis	1.65e-05	0.000401	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IRS2—osteoporosis	1.64e-05	0.000398	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MGLL—osteoporosis	1.63e-05	0.000396	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—LEP—osteoporosis	1.62e-05	0.000392	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP19A1—osteoporosis	1.61e-05	0.00039	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IRS2—osteoporosis	1.6e-05	0.00039	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—LEP—osteoporosis	1.6e-05	0.000389	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—LEP—osteoporosis	1.57e-05	0.000381	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CALCA—osteoporosis	1.54e-05	0.000375	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ESR1—osteoporosis	1.54e-05	0.000375	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ESR1—osteoporosis	1.53e-05	0.000372	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IRS2—osteoporosis	1.51e-05	0.000366	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	1.5e-05	0.000366	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ESR1—osteoporosis	1.5e-05	0.000364	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—LEP—osteoporosis	1.47e-05	0.000358	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IRS1—osteoporosis	1.44e-05	0.00035	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IRS1—osteoporosis	1.43e-05	0.000347	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ESR1—osteoporosis	1.41e-05	0.000342	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KL—osteoporosis	1.4e-05	0.00034	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IRS1—osteoporosis	1.4e-05	0.00034	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADCY5—osteoporosis	1.4e-05	0.000339	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ENO1—osteoporosis	1.39e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—osteoporosis	1.39e-05	0.000337	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—IDH2—osteoporosis	1.39e-05	0.000337	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—osteoporosis	1.38e-05	0.000334	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TGFB1—osteoporosis	1.37e-05	0.000334	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PSMA2—osteoporosis	1.37e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PSMA5—osteoporosis	1.37e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—osteoporosis	1.37e-05	0.000332	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6R—osteoporosis	1.35e-05	0.000329	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SPP1—osteoporosis	1.35e-05	0.000328	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—osteoporosis	1.35e-05	0.000328	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6R—osteoporosis	1.34e-05	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1—osteoporosis	1.33e-05	0.000324	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	1.33e-05	0.000324	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1—osteoporosis	1.32e-05	0.000322	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6R—osteoporosis	1.32e-05	0.000319	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IRS1—osteoporosis	1.32e-05	0.000319	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ADCY5—osteoporosis	1.31e-05	0.000319	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—osteoporosis	1.31e-05	0.000318	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.3e-05	0.000316	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1—osteoporosis	1.3e-05	0.000315	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ACP5—osteoporosis	1.27e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—osteoporosis	1.27e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6R—osteoporosis	1.24e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS2—osteoporosis	1.22e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1—osteoporosis	1.22e-05	0.000296	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—osteoporosis	1.21e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—osteoporosis	1.2e-05	0.00029	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPI1—osteoporosis	1.18e-05	0.000286	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—osteoporosis	1.14e-05	0.000277	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP19A1—osteoporosis	1.11e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—P4HB—osteoporosis	1.11e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	1.1e-05	0.000267	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GAPDH—osteoporosis	1.09e-05	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS1—osteoporosis	1.07e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPP1—osteoporosis	1.06e-05	0.000258	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RAP1A—osteoporosis	1.06e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—osteoporosis	1.03e-05	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—osteoporosis	1.02e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—osteoporosis	1.01e-05	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6R—osteoporosis	1e-05	0.000243	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—osteoporosis	9.92e-06	0.000241	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—osteoporosis	9.88e-06	0.00024	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—osteoporosis	9.65e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS2—osteoporosis	9.6e-06	0.000233	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—osteoporosis	9.4e-06	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—osteoporosis	9.32e-06	0.000226	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADCY5—osteoporosis	9.08e-06	0.00022	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—osteoporosis	9.05e-06	0.00022	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—osteoporosis	8.97e-06	0.000218	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO1—osteoporosis	8.56e-06	0.000208	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMA2—osteoporosis	8.44e-06	0.000205	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMA5—osteoporosis	8.44e-06	0.000205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS1—osteoporosis	8.38e-06	0.000204	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—osteoporosis	8.35e-06	0.000203	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—osteoporosis	8.07e-06	0.000196	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—osteoporosis	8.02e-06	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—osteoporosis	8e-06	0.000194	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—osteoporosis	7.96e-06	0.000193	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—osteoporosis	7.94e-06	0.000193	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6R—osteoporosis	7.88e-06	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—osteoporosis	7.79e-06	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—osteoporosis	7.78e-06	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—osteoporosis	7.77e-06	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—osteoporosis	7.56e-06	0.000184	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—osteoporosis	7.32e-06	0.000178	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—osteoporosis	7.3e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—osteoporosis	6.84e-06	0.000166	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—osteoporosis	6.68e-06	0.000162	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—osteoporosis	6.03e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—osteoporosis	5.98e-06	0.000145	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—osteoporosis	5.94e-06	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—osteoporosis	5.94e-06	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—osteoporosis	5.92e-06	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—osteoporosis	5.86e-06	0.000142	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADCY5—osteoporosis	5.59e-06	0.000136	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—osteoporosis	5.57e-06	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—osteoporosis	5.5e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—osteoporosis	5.14e-06	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—osteoporosis	4.67e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	4.66e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—osteoporosis	4.46e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—osteoporosis	4.11e-06	9.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—osteoporosis	3.51e-06	8.52e-05	CbGpPWpGaD
